Type and dose of drugs used for conditioning regimen.
收藏数据链接：
官方服务：
资源简介：
*with total body irradiation, 12–14.4Gray.
应用场景：
创建时间：
2015-12-02
相关数据集
Baseline characteristics, supportive care and clinical outcomes of Class III patients receiving different conditioning regimens.
aBuCy: Busulfan + Cyclophosphamide; *ALT: Alanine aminotransferase. bTreoFluT: Treosulfan, fludarabine and thiotepa; ∧AST: Aspartate aminotransferase. @BM: Bone marrow; #PBSC: Peripheral blood stem ce
NIAID Data Ecosystem40
Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease
The management of high-risk acute myeloid leukaemia (AML) remains challenging, highlighting the need for innovative conditioning strategies beyond current regimens. In the present single-arm study, a
Figshare2024-12-28 更新30
Efficacy and safety of anti-CD45-saporin as conditioning agent for RAG deficiency
TITLE: Efficacy and safety of anti-CD45–saporin as conditioning agent for RAG deficiency Maria Carmina Castiello, Marita Bosticardo, Nicolò Sacchetti, Enrica Calzoni, Elena Fontana, Yasuhiro Yamazak
NIAID Data Ecosystem20
DataSheet_1_Decitabine-Intensified Modified Busulfan/Cyclophosphamide Conditioning Regimen Improves Survival in Acute Myeloid Leukemia Patients Undergoing Related Donor Hematopoietic Stem Cell Transplantation: A Propensity Score Matched Analysis.docx
To identify the benefit of decitabine (Dec)-intensified myeloablative conditioning on the outcomes of patients with acute myeloid leukemia (AML) after related donor hematopoietic stem cell transplanta
NIAID Data Ecosystem30
Characteristics of patients, according to myeloablative (MA) and Reduced intensity (RIT) conditioning regimens.
Activity disease: chronic myeloid leukemia in accelerated phase, acute leukemia was more than two induction therapies with residual leukemia cells or failed to achieve remission.
NIAID Data Ecosystem20
